REGULUS THERAPEUTICS INC (RGLS) Stock News
NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD
RGLS Latest News, Press Relases and Analysis
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a...
Should You Buy Regulus (RGLS) After Golden Cross?
Is it a good or bad thing when a stock experiences a golden cross technical event?
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion
Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
Mentions: NVS
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Why MP Materials Stock Was a Massive Winner This Week
Rare earth miner and processor MP Materials (NYSE: MP) had quite the week to remember, both operationally and on the stock market. On the back of some quite favorable news, the company's shares raced more than 16% higher over the course of the week, according to data compiled by S&P Global Market Intelligence. MP Materials owns and operates the only rare earth mine in the U.S. Rare earths, for those unfamiliar, are metals that are used in the manufacture of specialty magnets used in popular high-tech products such as smartphones.
Is Microbot Medical Inc. (MBOT) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Microbot Medical Inc. (NASDAQ:MBOT) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...